❌

Normal view

There are new articles available, click to refresh the page.
Today — 18 November 2026Main stream

Study: Menstrual Cycle Irregularities Linked to ADHD, Depression, Anxiety in Girls

18 November 2026 at 02:40

November 17, 2026

Several menstrual cycle characteristics, including timing of menarche, cycle regularity, menstrual pain, and severity of premenstrual symptoms, are associated with more common and severe symptoms of depression, anxiety, and ADHD in adolescent girls, according to a recent study published in European Child & Adolescent Psychiatry.1

The longitudinal study followed 5,673 adolescent girls, ages 9 to 11, over a seven-year period, with annual assessments up to ages 14 to 17.

Premenstrual Symptoms & Menstrual Pain Linked to ADHD Symptoms

Study participants self-reported the severity of premenstrual symptoms, such as irritability and fatigue, and the intensity of period pain (categorized as mild, moderate, or severe). Findings showed that severe menstrual pain was associated with higher anxiety, depression, and ADHD symptoms.

Premenstrual symptoms demonstrated a graded pattern in their association with mental health outcomes. Mild premenstrual symptoms were linked to higher anxiety symptom scores. Moderate premenstrual symptoms were linked to higher anxiety and depression symptom scores. Severe premenstrual symptoms were linked to higher anxiety, depression, and ADHD symptom scores.

The researchers offered several social and biological factors as potential explanations for these results.

“Psychosocially, menstrual pain and [premenstrual symptoms] may result in functional impairment – including missed school, disrupted sleep, reduced social participation – which may contribute to emotional distress,” they wrote.

The Role of Inflammatory and Pain Pathways

The study explained that intense period pain and premenstrual distress may activate inflammatory and pain-sensitivity pathways, increasing vulnerability to anxiety and depression. Researchers also noted that the neurobiological mechanisms for processing pain may overlap with those involved in attention and focus, which could help explain the connection between menstrual pain and ADHD symptoms.

Researchers also suggested that fluctuating estrogen and progesterone may help to explain the connection between severe premenstrual symptoms and higher anxiety, depression, and ADHD symptom scores. These hormones heavily affect serotonin, dopamine, and GABA in the brain. Serotonin is linked to mood; dopamine controls motivation and reward processing; and GABA is crucial for emotional processing and regulation. When hormones fluctuate before a menstrual cycle, these neurotransmitters are impacted too, which, in turn, may influence symptoms of anxiety, depression, and ADHD.

The Lived Experience of Women with ADHD

The relationship between ADHD and hormonal fluctuations is a pressing subject for many ADDitude readers with lived experience. In an ADDitude survey of nearly 2,000 women with ADHD, almost one in two respondents said that hormonal fluctuations had a “life-altering” or “severe” impact on their ADHD.

“I know that the week before my period I am a complete mess,” Addison, an ADDitude reader, said. “I have to prepare for the fact that my world feels like it’s falling apart emotionally, and I hate the way that I look the most that week. These are weeks I often avoid being with people, as I know I am not the most positive and am the most sensitive.”

“I used to have lots of irritability, food cravings, tiredness, and was fuzzy-headed three to four days before my period started,” said Connie, another reader.

“I suffer from symptoms like uncontrolled fits of anger and crying spells and feeling extremely overwhelmed the days before my period. I’m even more moody, irritable and have more trouble concentrating,” said ADDitude reader Elena.

Moreover, women with ADHD are disproportionately affected by premenstrual disorders with more than 40% of women with ADHD experiencing premenstrual dysphoric disorder (PMDD) compared to 3% to 9% of women overall.2, 3 PMDD is also heavily tied to hormonal shifts and mental health.

“PMDD is caused by a high sensitivity to fluctuations in estrogen and progesterone, as well as decreases in serotonin – hormonal changes that happen during the luteal phase of the menstrual cycle,” wrote Dara Abraham, D.O. in an ADDitude article. “During the luteal phase that follows ovulation, estrogen decreases, as do dopamine, serotonin, and eventually progesterone. These changes cause painful and distressing symptoms until the menstruation begins and hormone levels rise again.”

Cycle Regularity and Menarche Linked to Depression & Anxiety Symptoms

The study also found that irregular menstrual cycles were linked to higher depression and anxiety symptom scores. The longer a girl had been having her menstrual cycles, the stronger the link between irregular periods and depression and anxiety symptoms became. Likewise, earlier age at menarche was associated with higher depression symptom scores.

While the study focused specifically on early age at menarche, previous research suggests that early puberty more broadly may have an association to ADHD.

“Researchers are examining why girls with ADHD have about twice the risk for early puberty, and why autistic girls are up to four times more likely to experience early puberty compared to other children,” wrote Molly Nikolas, Ph.D. in an ADDitude article. “In addition to higher rates of obesity and social stress, which could accelerate the onset of puberty, neurodivergent girls may experience differences in dopamine activity, stress response, and immune and neuroendocrine systems — all of which may affect sexual development.”

What This Means for Future Studies & Patient Care

The researchers listed several limitations to the study. Menstrual cycle characteristics were gathered through an annual self-report, and parents reported mental health symptoms. In addition, the relationship between menstrual characteristics and mental health symptoms may be bidirectional. The researchers also reported the associations were modest and that future studies are needed to further explore the potential social and biological mechanisms involved.

The study’s authors said they hope their findings will help healthcare professionals consider menstrual cycle characteristics as potentially meaningful insight when evaluating the mental health of adolescent girls.

Sources

1 Marla, S., Gangaraju, S.H., Nguyen, J. et al. Association between menstrual cycle characteristics and mental health in early adolescence. Eur Child Adolesc Psychiatry 35, 4035–4049 (2026). https://doi.org/10.1007/s00787-026-03163-8 

2 Team, A. E. (2025). PMDD and ADHD: Understanding the connection and managing symptoms. ADDA – Attention Deficit Disorder Association. https://add.org/pmdd-and-adhd/

3 Pooja Thakrar, Kalyani Bhukar, Rajat Oswal, Premenstrual dysphoric disorder: Prevalence, quality of life and disability due to illness among medical and paramedical students. Journal of Affective Disorders Reports, Volume 4, 2021, 100112, ISSN 2666-9153, https://doi.org/10.1016/j.jadr.2021.100112

Before yesterdayMain stream

New Research: Sex Differences Impact ADHD Symptoms, Treatment Efficacy

16 September 2026 at 18:57

September 15, 2026

Sex differences exert a significant and complex impact on ADHD symptoms, treatment, and risk of co-occurring conditions, according to the findings of several recent studies.

Most recently, researchers from Denmark found that individuals with ADHD faced relatively greater risk of developing 13 physical conditions, and that risk ratio was significantly affected by the sex of the patient.1 Research on the impact of menstrual cycle hormones on ADHD symptoms further illuminated the notable influence of sex on ADHD symptomatology and impairment.2 Finally, a study on the efficacy of cognitive behavioral therapy (CBT) for adolescents with ADHD also revealed differences across the sex divide.

Sex Impacts Risk of Physical Conditions

People with ADHD demonstrate a higher risk for 13 physical conditions, including endocrine, metabolic, and eye conditions, according to a study that used medical records of more than 800,000 Danish individuals. The study, published in the Journal of Attention Disorders, found that individuals diagnosed with ADHD showed a higher risk for all conditions, apart from malignant neoplasms, beginning in adolescence.

Having an ADHD diagnosis did not raise this risk equally for men and women, however.

In the general population, females were at a higher risk of most physical conditions beginning in adolescence. Specifically, females were nine times more likely to have an endocrine, nutritional, or metabolic disorder beginning in young adulthood. However, when researchers measured rates in females with an ADHD diagnosis, the relative prevalence fell by half.

In another case, males in the general population had a 15% higher risk than females of developing eye and adnexa diseases in childhood. Among those with an ADHD diagnosis, though, this trend was reversed; females had double the risk of males.

Sex and Hormonal Fluctuations Impact Symptoms

One notable difference in ADHD presentations between males and females stems from fluctuating symptoms over the menstrual cycle. The impact of estrogen on ADHD has been a primary research focus for Michelle Martel, Ph.D., chair of the psychology department at the University of Kentucky, who wrote this in the ADDitude article “Hormonal Changes in Women with ADHD: 4 Gaping Holes in Research:” “Each menstrual cycle brings hormonal peaks and valleys that significantly influence ADHD symptoms. Our recent research confirms that anxiety, mood, and attention all worsen as estrogen falls during the luteal phase.”

Prompted by the promising findings of a small study in 2018,4 Martel conducted a larger-scale study on ADHD symptoms and menstrual hormones. She recently presented her findings at the U.S. Psychiatric and Mental Health Congress.

Martel’s team collected daily measurements of hormone levels and ADHD symptoms from 97 female college students with an ADHD diagnosis and found ADHD symptoms, including impulsivity and inattention, increased in the days preceding and beginning their period.

“These studies have dramatic assessment and treatment implications,” Martel stated in a press release. “We should be paying attention to these things when we’re doing assessments, and then also we may want to change our treatments or personalize our treatments based on where women and girls are across their lifespan.”

Sex Impacts Efficacy of Treatment

A third study exploring yet another facet of sex differences focused on the varying impact of CBT on adolescent males and females with ADHD. Data from 200 teens who participated in randomized control trials in Norway or the Netherlands was analyzed.

According to parent reports, CBT significantly improved ADHD symptoms generally, however this improvement varied depending on the patient’s sex as well as accompanying symptoms of depression.

  • CBT led to a significantly smaller reduction in ADHD symptoms for girls with higher levels of depression symptoms, compared to boys with these symptoms.
  • For girls, receiving individual CBT (versus group CBT), led to double the improvement in ADHD symptoms.

Each of these studies sheds light on the highly complex and variable nature of ADHD symptoms, treatment, and co-occurring conditions and the still poorly understood ways in which sex differences may affect these realms.

Sources

1Villumsen, M. D., Bilenberg, N., & Steinhausen, H.-C. (2026). Sex Differences in the Association Between Attention-Deficit Hyperactivity Disorder and Physical Diseases in Childhood and Adolescence Using Nationwide Birth Cohorts. Journal of Attention Disorders, 0(0). https://doi.org/10.1177/10870547261448260/

2Harper K. How menstrual periods can affect ADHD symptoms and treatment. Scientific American. May 2026. https://www.scientificamerican.com/article/adhd-symptoms-can-fluctuate-with-the-menstrual-cycle/

3Hanes, T. K., Andersen, A. C., Boyer, B. E., & Wagner, K. (2026). Gender Differences in Cognitive Behavioral Therapy Outcomes for Adolescents With ADHD: Examining the Impact of Internalizing Symptoms. Journal of Attention Disorders, 30(7), 945-954. https://doi.org/10.1177/10870547251415431

4Roberts B, Eisenlohr-Moul T, Martel MM. Reproductive steroids and ADHD symptoms across the menstrual cycle. Psychoneuroendocrinology. 2018;88:105-114. doi:10.1016/j.psyneuen.2017.11.015.

Could ADHD Medications Treat Coexisting Depression and Anxiety? New Studies Say Yes.

26 August 2026 at 21:23

August 26, 2026

ADHD medications decrease antidepressant usage and reduce symptoms of depression and anxiety in people diagnosed with attention deficit, suggest findings from three new studies.

Antidepressant and psychotropic medication use in adults often precedes an ADHD diagnosis; however, a new landmark study published in Acta Psychiatrica Scandinavica152 found that use of selective serotonin reuptake inhibitors (SSRIs) and other antidepressants decreased substantially after adults received an ADHD diagnosis and began treatment with a stimulant or non-stimulant medication.1

Women received antidepressant prescriptions prior to an ADHD diagnosis much more often than did men, according to the Finnish cohort study of 322,416 adults (66,146 with ADHD and 256,270 without). The researchers attribute this to clinicians misinterpreting or misdiagnosing ADHD symptoms as anxiety or depression in women. Depression and anxiety can also result from living with untreated ADHD. As many as 80% of adults with ADHD have at least one coexisting psychiatric disorder; the most common are generalized anxiety, social anxiety, and depression. 2

“ADHD is often associated with coexisting psychiatric conditions,” the researchers wrote. “Differential diagnosis between other conditions and ADHD is not always clear, and patients are sometimes initially treated for another disorder instead.”

Findings from the study support this: At the second-year follow-up, the use of SSRIs, benzodiazepine derivatives, diazepines, oxazepines, thiazepines and oxepines, and other antidepressants decreased in the ADHD cohort. However, SSRI and other antidepressant usage increased in the non-ADHD group during the same period.

Following an ADHD diagnosis, most patients were motivated to try ADHD medication: 95% of patients filled the prescribed medication; 80% of those bought the medication within 10 days. More than half of patients (56.5%) purchased extended-release methylphenidate (brand name: Ritalin).

Just one quarter of late-diagnosed adult patients with ADHD maintained continuous ADHD medication for five years or more.

“This indicates that ADHD drugs were not massively misused, as large purchases would be indicative of [abuse],” the researchers said. “Discontinuation may stem from symptom alleviation, adverse effects, or refinement of diagnoses.”

The study, which analyzed data from Finnish national registers between 2015 and 2020, also found that children and adolescents diagnosed later with ADHD used more antibiotics and anti-inflammatory drugs than did matched controls. After the children began ADHD treatment, the use of these drugs decreased more than it did in controls.

The researchers wrote that “future research is needed, for example, about possible anti-inflammatory effectiveness of ADHD medications, like that of selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors.”

While the Finnish study broadly evaluated how an ADHD diagnosis and subsequent treatment influences antidepressant usage, two new clinical trials took a deeper look into whether a single-medication approach could treat ADHD and co-occurring depression and/or anxiety.

Stimulant Treatment for Co-Occurring Anxiety

During an 8-week Phase 3b clinical trial, centanafadine (brand name: Simtriyo), a first-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) and central nervous system (CNS) stimulant, delivered statistically significant, clinically relevant improvements in both ADHD and anxiety symptoms.3 Centanafadine received FDA approval for the treatment of ADHD in adults and pediatric patients aged 6 years and older on July 24, 2026.

The trial included 315 adults, aged 18 to 65 years, with ADHD and coexisting generalized or social anxiety disorder. Study participants received either centanafadine XR 280mg or placebo once daily. The study analyzed symptom improvements using the Adult Investigator Symptom Rating Scale (AISRS) and the Hamilton Anxiety Rating Scale (HAM-A).

Non-Stimulant Treatment for Coexisting Depression and Anxiety

Another recent clinical trial published in The Journal of Clinical Psychiatry that adults with ADHD and coexisting depression and/or anxiety symptoms experienced substantial improvement in all three conditions while taking the non-stimulant viloxazine ER (brand name: Qelbree) extended-release capsules alone or in addition to existing treatments.4

During the open-label Phase 4 trial, 150 participants received 200mg of viloxazine ER once daily, with doses increasing up to 600mg. At week 14, the AISRS results showed improved ADHD symptoms and a significant reduction in total baseline AISRS scores. Depression and anxiety rating scales also showed significant improvement in symptoms from baseline to week 14: 71.8% of participants achieved a 30% reduction in AISRS total score, and half of the participants reduced their AISRS total score by 45.6%.

This was the first clinical trial of viloxazine ER in adults with ADHD to include participants with coexisting depression and/or anxiety and to allow concurrent medication use. In addition to viloxazine ER,

  • 28.6% of participants used stimulant medications
  • 44.7% of participants used antidepressants
  • 14.9% of participants used anxiolytic and/or hypnotic medications

Viloxazine ER is an FDA-approved non-stimulant medication for children, ages 6 years or older, and adults with ADHD. 5 It is not approved as an antidepressant in the U.S. However, studies from the 1970s found viloxazine demonstrated antidepressant effects 6 In Europe, viloxazine was approved and used as an immediate-release drug for depression for approximately 30 years before being discontinued for commercial reasons unrelated to efficacy or safety. 7

Clinical Implications

More research is needed to determine whether ADHD medications effectively treat coexisting depression and/or anxiety or if symptom reduction is related to improvements in ADHD symptoms. However, one consistent takeaway from all these studies is the utility of ADHD medications.

The potential benefits of using one medication to treat both ADHD and coexisting depression and/or anxiety could improve safety and medication adherence issues for patients who already have executive function deficits.

“Simultaneous treatment of ADHD and depression and/or anxiety symptoms can be challenging, partly due to safety concerns about combining medications,” the authors of The Journal of Clinical Psychiatry article wrote.

Fewer prescription medications could also translate to greater cost savings for patients.

The steep out-of-pocket costs of ADHD care today — on average, more than $8,500 per child and $4,700 per adult annually — are driving families to ration medication, delay or skip medical appointments, and forgo interventions they rely on to function well, according to ADDitude’s Cost of ADHD Diagnosis & Treatment survey. Of the 1,970 survey respondents, 10% said their ADHD care costs exceeded 10% of their income.

“I just go without medication when I run short of money,” a respondent said.

“I never take my clinician-recommended dosage because I can’t afford it,” another survey respondent said.

“We are paying out-of-pocket for medication, so our kids don’t take it on weekends or vacations,” another mother commented.

“As with any treatment, the best approach to treating depression and/or anxiety and ADHD depends on the patient’s individual needs,” says Roberto Olivardia, Ph.D., who recommends clinicians consider both psychological and psychopharmacological treatments when treating patients with ADHD and coexisting anxiety and/or depression.

“Dealing with ADHD symptoms is challenging enough,” Olivardia says. “Dealing with depression or anxiety, too, is debilitating. Only with proper assessment and diagnosis can treatment for both, or either, be possible.”

Sources

1Westman, E., Prami, T., Kallio, A. et al. (2025). Use of antidepressants decreased after initiation of ADHD treatment in adults — a Finnish nationwide register study describing use of ADHD and non-ADHD medication in people with and without ADHD. Acta Psychiatrica Scandinavica152. https://doi.org/10.1111/acps.70007

2Katzman, M.A., Bilkey, T.S., Chokka, P.R., Fallu, A., & Klassen, L.J. (2017). Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. https://doi.org/10.1186/s12888-017-1463-3

3P3b short-term study of CTN in patients with ADHD and comorbid anxiety. ClinicalTrials.gov. May 6, 2026. Accessed July 1, 2026. https://clinicaltrials.gov/study/NCT06973577

4Adler, L.A., Lieberman, V.R., Brijbasi, L., Mattingly, G.W., et al. (2026). Viloxazine extended release in adults with attention-deficit/hyperactivity disorder and depression and/or anxiety symptoms: results from a decentralized, open-label, phase 4 trial. J Clin Psychiatry. https://doi.org/10.4088/JCP.25m16234

5Qelbree (viloxazine extended-release capsules). Prescribing information. In: Supernus Pharmaceuticals. Inc.; 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211964s013lbl.pdf

6Greenwood D. (1975). Animal pharmacology of viloxazine (Vivalan). J Int Med Res.

7Findling, R.L., Candler, S.A., Nasser, A.F., et al. (2021). Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. https://doi.org/10.1007/s40263-021-00825-w

Prenatal Antidepressant Use Not Linked to ADHD in Kids: New Study

14 July 2026 at 21:13

July 14, 2026

Parental use of antidepressants during pregnancy does not cause ADHD or autism in their offspring, according to a new study published in The Lancet Psychiatry.1  This large-scale systematic review included data from 25 million pregnancies, analyzing maternal use of antidepressants during pregnancy, paternal use during pregnancy, and maternal use pre-conception, to explore any potential relationship between medication use and later emergence of neurodevelopmental disorders in children.

Though a slight association was found between maternal antidepressant use in pregnancy and ADHD as well as ASD (relative risk [RR], 1.13), this link ceased to exist after the researchers adjusted for confounding factors, including the genetic influence of parents’ psychiatric health and familial factors.

Further, researchers found that paternal antidepressant use during pregnancy was also linked to increased ADHD risk (RR, 1.46) and ASD risk (RR, 1.28), confirming that any association between antidepressants and later ADHD was likely caused by the high degree of heritability of ADHD, and its common comorbidity with depression.

Though older research found an association between parental antidepressant use and ADHD in offspring, causing some concern among expectant mothers, these studies did not control for confounding variables. As later research adjusted for the influence of maternal and paternal psychiatric and neurodevelopmental history, associations have been deemed largely insignificant.

“We know many parents-to-be worry about the potential impact of taking medication during pregnancy,” said co-author of the study Wing Chung Chang, M.D., from the University of Hong Kong, in a statement. “Our study provides reassuring evidence that commonly used antidepressants do not increase the risk of neurodevelopmental disorders. While all medications carry risks, so too does stopping antidepressants during pregnancy due to an increased risk of relapse.”

SSRI Use Common Among Those with ADHD

In a recent ADDitude webinar titled “Identifying Co-Occurring Mood Disorders in Adults with ADHD,” Desiree Matthews, MSN, spoke about the shared genetic underpinnings that explain the high co-occurrence of ADHD and mood disorders. “Up to 70% of adults living with ADHD have at least one co-occurring condition,” said Matthews, founder of Different Mental Health Program. “Studies show that ADHD crosses over with shared genes that may be responsible for anxiety disorders as well as mood disorders such as depression, PTSD, or bipolar disorder.”

Research has found that postpartum depression (PPD), also called perinatal depression, is significantly more common in women with ADHD than it is in their neurotypical counterparts: 17% of women with ADHD had PPD, compared to 3.3% without ADHD.2

Though PPD often emerges after childbirth, it can be present during pregnancy as well.

The medications used to treat these disorders — typically, antidepressants such as selective serotonin reuptake inhibitors (SSRIs) — are frequently used by individuals who have ADHD, including some pregnant women. “Not surprisingly, the most common medication prescribed alongside ADHD medication is an SSRI,” Matthews explained. “They are cost-effective. They’re widely accessible.”

Swift treatment of mood disorders is critical, Matthews explained, as leaving depression untreated can have fall-on effects. “Remission should be the goal when we think about depression, not only because we want to have full restoration of functioning, but because it changes the prognosis of the disorder in terms of treatment and relapse,” Matthews said. “If we don’t address these symptoms as quickly as possible, there is a higher chance the depression will come back.”

Source

1Chan J, Zhong A, Lam J et al. Maternal and paternal antidepressant use before and during pregnancy and offspring risk of neurodevelopmental disorders: a systematic review and meta-analysis. The Lancet Psychiatry, 13, 472-484

 

2Andersson, A., Garcia-Argibay, M., Viktorin, A., Ghirardi, A., Butwicka, A., Skoglund, C., Bang Madsen, K., D’onofrio, B.M., Lichtenstein, P., Tuvblad, C., and Larsson, H. (2023). Depression and Anxiety Disorders During the Postpartum Period in Women Diagnosed with Attention Deficit Hyperactivity Disorder. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2023.01.069

Why Do ADHD and Mood Disorders So Often Overlap?

8 July 2026 at 21:02

Up to 70% of adults with ADHD have at least one co-occurring condition. Mood disorders like anxiety and depression are the most common “comorbidities,” though that term insufficiently captures the realities of living with multiple conditions.

“I really like to think of this as more of a multi-morbidity,” said Desiree Matthews, MSN, PMHNP-BC, during her July ADDitude webinar, “Identifying Co-Occurring Mood Disorders in Adults with ADHD.” “People can have prominent major depressive disorder or generalized anxiety disorder along with ADHD, and both could be equally impairing, maybe in different ways.”

Which is why thorough evaluations and accurate diagnoses are crucial — a critical issue when mood disorders are still frequently overlooked or misdiagnosed.

ADDitude Webinar Poll

Which of the following conditions were you diagnosed with prior to your ADHD diagnosis? Please select all that apply.

  • Anxiety34.36%
  • Major depressive disorder25.77%
  • PTSD7.36%
  • Bipolar disorder5.37%
  • None of the above27.15%

447 respondents

If a mood disorder diagnosis preceded your ADHD diagnosis, did you struggle or are you struggling to get an evaluation for ADHD?

  • Yes29.8%
  • No26.27%
  • Not applicable43.93%
  • 451 respondents

Here are our main takeaways on the overlap between ADHD and mood disorders from Dr. Matthews’ webinar.

Shared Pathways Explain Multi-Morbidity

Why does ADHD frequently co-occur with so many other conditions, particularly mood disorders? These conditions likely share root causes, according to Matthews.

“Many of the risk factors in our genes are risk factors for more than one mental health disorder,” she said.

As far as neurobiological underpinnings, researchers are also taking a closer look at serotonin, a neurotransmitter that regulates mood, sleep, impulse control, appetite, and cognition. “We can see dysregulation in serotonergic pathways in ADHD but also in depression, anxiety, and bipolar disorders,” Matthews said.

[Read: When a Mood Disorder Looks Like ADHD — and Vice Versa]

On Comorbidities and Sex Differences

Why do women tend to have higher rates of anxiety, depression, and bipolar disorder compared to men? The answer may lie, in part, in differences in how the sexes synthesize certain neurotransmitters. Men, for example, have greater serotonergic capacity than women. Since serotonin can buffer stress, this may explain why women are at greater risk for mood disorders compared to their male counterparts.

How to Tell If It’s More Than ADHD

Complicating accurate diagnosis is that symptoms are transdiagnostic. Issues with attention and executive function — core features of ADHD — are also seen in anxiety disorders, for example. It’s why thorough screenings matter, even if a diagnosis already exists. “Going with [the patient’s] chief complaint can lead us astray, whether we are missing or making a misdiagnosis,” Matthews said.

One question to help patients and clinicians consider if there’s more beneath the surface: Is treatment improving quality of life? If ADHD treatment is improving focus, but poor sleep and emotional distress persist, then it’s time to consider an additional evaluation.

Screeners are easily accessible tools that can help get a conversation started with a healthcare provider or a loved one. The Rapid Mood Screener, for example, is a tool that helps to differentiate bipolar disorder from major depressive disorder.

ADHD and Mood Disorders Can Be Safely Treated Together

From new medications for treatment-resistant conditions and non-pharmacological options like neuromodulation, psychotherapy, and prescription digital therapies, there are several options for safely and effectively managing ADHD with anxiety, depression, bipolar disorder, complex PTSD, and more.

Treatment is certainly not one-size-fits-all, and in some cases, the most impairing condition must be treated first rather than both conditions treated concurrently. For comorbid bipolar disorder and ADHD, for example, the former is treated first. Providers should also monitor patients to ensure that treatment combinations do not result in activation, insomnia, or mood destabilization.

For more insights on identifying co-occurring mood disorders with ADHD, watch the full webinar at additu.de/070826

Mood Disorders and ADHD: Next Steps


ADDITUDE IS HUMAN
Artificial intelligence does not create or edit any written content published by ADDitude. Our editorial team is 100% human, and our mission is simple: listen to and serve our readers with hand-crafted, expert-informed resources. To support ADDitude, please consider subscribing. Your readership and support help make our commitment possible. Thank you.

Can We Talk About Suicide Among Men with ADHD?

1 June 2026 at 07:38

The core symptoms of ADHD, including impulsivity, emotional dysregulation, and common co-occurring disorders like depression and anxiety, contribute to a higher risk of suicide in men with the condition. Treating ADHD with medication has been shown to significantly reduce that risk.

Prevention begins by recognizing the association between suicidality, ADHD, and co-occurring conditions. To understand the scope of this crisis, consider the data: In 2023, according to the most recent statistics, 49,316 suicides were recorded in the U.S.; males accounted for more than two-thirds of those deaths.

In Sweden, a study found that males with ADHD had nearly triple the risk of suicide compared to males without ADHD. A Canadian study found that men with ADHD were about four times more likely to report a suicide attempt than their peers without the condition.

Although co-occurring disorders like depression and anxiety were contributing factors, researchers found a higher risk among people with ADHD even after controlling for these associated conditions. It should be noted that females with ADHD also face an elevated risk of suicide.

[Read: The Hidden Complexities of Men with ADHD]

The Loneliness of Not Belonging

To understand how core symptoms of ADHD contribute to an increased risk for suicide, we can apply the empirically validated “Interpersonal-Psychological Theory of Suicidal Behavior.”

This framework posits that suicidal ideation can result from a lack of caring, reciprocal relationships, and/or feelings of deep loneliness, even when someone is in a relationship. The capability for suicide, according to this theory, stems from those factors combined with an “acquired ability to enact lethal self-injury.”

Multiple factors can contribute to the feeling among boys and men with ADHD that they don’t belong:

  • The negative impact of untreated symptoms on their social and personal relationships
  • A higher risk of being bullied
  • An increased prevalence of depression
  • A higher risk of learning disabilities that, along with ADHD, can lead to feeling like the academic environment was not designed for their learning needs.

[Read: For Men With ADHD — and Those Who Love Them]

A sense of burdensomeness can, unfortunately, be normative for those with ADHD, as executive functioning challenges lead to feelings of inferiority, helplessness, and exhaustion. Asking for support can be difficult for males, as societal messages equate needing help with a diminished sense of masculinity. Boys and men with ADHD often require scaffolding, but asking for such support leave them feeling like unsuccessful, dependent burdens on others — a vicious cycle.

Lastly, an acquired ability to enact lethal self-injury stems from a diminished fear of death and an increased pain tolerance, which is learned through repeated exposure to painful or fear-provoking experiences. These behaviors overcome self-preservation and enable suicidal behavior, distinguishing suicidal thoughts from actions. These factors chillingly shed light on why ADHD is associated with this dark risk, including higher rates of physical and sexual trauma, higher risk of childhood accidents and injuries, attraction to adrenaline-fueled dangerous activities, higher risk of substance use, and other self-harm behaviors.

ADHD Medication Lowers Risk

Treating ADHD effectively is associated with a significant reduction in suicide risk for men with ADHD. A 2019 study of more than 2 million males with ADHD found a 30% to 40% decreased risk of suicide attempts during months they were on stimulant medication compared with months they were not.

Also compelling is a study of almost 85,000 Taiwanese youth, who were followed by researchers over a 16-year period. Even after adjusting for confounding disorders, 90 to 180 days of methylphenidate treatment was associated with a 59% risk reduction for suicide attempts, and 180 days or more of treatment was associated with a 72% risk reduction.

All of this points to the seriousness of untreated ADHD and its implications: Proper diagnosis and treatment save lives. In addition, societal pressures to “man-up” leave many boys and men feeling that they lose status by asking for help or availing themselves of treatment, even when they are diagnosed. That needs to change. Not getting the support they need costs many males something far greater than their status.

ADHD and Suicide in Men with ADHD: Next Steps

Roberto Olivardia, Ph.D., is a clinical psychologist and clinical instructor of psychology at Harvard Medical School. He is the co-author of The Adonis Complex: The Secret Crisis of Male Body Obsession.


ADDITUDE IS HUMAN
Artificial intelligence does not create or edit any written content published by ADDitude. Our editorial team is 100% human, and our mission is simple: listen to and serve our readers with hand-crafted, expert-informed resources. To support ADDitude, please consider subscribing. Your readership and support help make our commitment possible. Thank you.

❌
❌